抗肿瘤抗生素力达霉素的发酵工艺  

Fermentation process of anti-tumor antibiotic lidamycin

作　　者：赵春燕[1] 姚恩泰[1] 王玉凤[1] 商悦[1] 李电东[1] 

机构地区：[1]中国医学科学院中国协和医科大学医药生物技术研究所,北京100050

出　　处：《中国新药杂志》2005年第9期1160-1162,共3页Chinese Journal of New Drugs

基　　金：国家自然科学基金资助(30472042)

摘　　要：目的:中试规模验证力达霉素发酵工艺的可行性。方法:采用微生物法、HPLC法和精原细胞法分析力达霉素中试发酵液及其发酵提取物,以力达霉素的生物效价为指标考察其发酵工艺。结果:5批200L发酵罐,平均每罐发酵液的微生物效价为450μg·mL-1,可获得力达霉素纯品5·7g。结论:多批中试结果表明:力达霉素目前使用发酵工艺较稳定,可以为进一步的分离纯化提供优质足量的发酵液,满足工业生产和进一步深入研究的需要。Objective： To validate the fermentation pilot process of lidamyein. Methods ： The fermented broth and its extracts of the lidamycin pilot process were analyzed by microbiological assay, HPLC and spermatogonial assay. The lidamycin titer was used as the optimal index in the evaluation of the fermentation process. Results： The analyses on five batches of the pilot fermentations （200 liter fermentor /each batch） showed that the mean titer of lidamycin reached 450 μg·mL^-1 Totally, 5.7 grams lidamycin was obtained from every batch of fermented broth. Conclusion ： This stable fermentation process might manufacture sufficient quantity and high quality of fermented broth for the isolation and purification of lidamycin in the industrial production scale.

关 键 词：力达霉素 发酵工艺 发酵液 

分 类 号：R979.14[医药卫生—药品]